<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0">

<channel>
<image>
<title>freepatentsonline.com</title>
<width>141</width>
<height>131</height>
<link>http://www.freepatentsonline.com/index.html</link>
<url>http://www.freepatentsonline.com/images/logo.gif</url>
</image>

<title>freepatentsonline.com: Drug, bio-affecting and body treating compositions</title>
<link>http://www.freepatentsonline.com/result.html?query_txt=ccl/514%20and%20isd/04/29/2008&amp;uspat=on</link>
<description>USPTO Class 514 Drug, bio-affecting and body treating compositions</description>
<language>en-us</language>
<lastBuildDate>Wed Apr 30 16:35:35 EDT 2008</lastBuildDate>

<item>
<title><![CDATA[Tendon-inducing methods]]></title>
<link>http://www.freepatentsonline.com/7365052.html</link>
<description><![CDATA[Compositions of proteins with tendon/ligament-like tissue inducing activity are disclosed. The compositions are useful in the treatment of tendinitis and tendon or ligament defects and in related tissue repair.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Modified 2′ and 3′-nucleoside prodrugs for treating <i>Flavivridae </i>infections]]></title>
<link>http://www.freepatentsonline.com/7365057.html</link>
<description><![CDATA[2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Animal body fat control]]></title>
<link>http://www.freepatentsonline.com/7365099.html</link>
<description><![CDATA[A method for controlling body fat in a human or nonhuman animal includes the step of reducing lipoxygenase activity in an animal. Lipoxygenase activity can be reduced by reducing the enzyme activity or by lowering the enzyme level. Reduced lipoxygenase activity correlates with reduced cell-associated LPL activity and with reduced cellular triacylglyceride level.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3)]]></title>
<link>http://www.freepatentsonline.com/7365096.html</link>
<description><![CDATA[Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Selective N-acylation of A82846 glygopeptides analogs]]></title>
<link>http://www.freepatentsonline.com/7365053.html</link>
<description><![CDATA[The present invention provides a process for selectively acylating an A82846A, A82846B, A82846C or PA-42867-A glycopeptide at the N1, N2 or N3 positions and the monoacylated compounds prepared therefrom.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Afamin-containing compositions and methods of use]]></title>
<link>http://www.freepatentsonline.com/7365049.html</link>
<description><![CDATA[The use of Afamin, in particular in combination with vitamin E is described for producing a preparation for the treatment of oxidative stress.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Dinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment]]></title>
<link>http://www.freepatentsonline.com/7365060.html</link>
<description><![CDATA[The present invention is related to a novel method for splitting nucleic acids at specific points on a complementary nucleic acid segment using a dinuclear copper-based compound of Formula I. Additionally, the present invention is related to a novel treatment of cancer, tumors, and cancer cells using a dinuclear copper-based compound of Formula I or a naked ligand of formula II: (Formula I and II).]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Photocrosslinked-polysaccharide composition and production process of the same]]></title>
<link>http://www.freepatentsonline.com/7365059.html</link>
<description><![CDATA[A process for producing a photocrosslinked-polysaccharide composition, which comprises: freezing a photoreactive polysaccharide-containing solution comprising a photoreactive polysaccharide in which a photoreactive group is bound to a polysaccharide, an aqueous solvent capable of dissolving the photoreactive polysaccharide, and any one substance selected from the group consisting of alcohol having compatibility with the aqueous solvent, a surfactant and a chelating agent; and irradiating the resulting frozen product with light, and a photocrosslinked-polysaccharide composition obtained by the process.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Pharmaceutical use of Graptopetalum and related plants]]></title>
<link>http://www.freepatentsonline.com/7364758.html</link>
<description><![CDATA[The present invention relates to compositions comprising  Graptopetalum  and uses thereof  Graptopetalum  can protect animals from liver diseases and medical conditions, such as inflammation, steatosis, and fibrosis. In particular,  Graptopetalum  inhibits proliferation of activated hepatic stellate cells, which play a pivotal role in liver fibrosis.  Graptopetalum  also has anti-fibrosis activities as well as inhibits proliferation of lung fibroblasts. Therefore, in addition to being a prophylactic and therapeutic agent for the liver,  Graptopetalum  is useful against fibrosis or inflammation of tissues or organs other than the liver, in particular lung, kidney, and bladder. Other plants in the family of Crassulaceae, particularly  Echeveria,  have similar effects as  Graptopetalum.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Use of at least one (dihydro)jasmonic acid derivative as a desquamating agent]]></title>
<link>http://www.freepatentsonline.com/7365097.html</link>
<description><![CDATA[Disclosed herein is the cosmetic use, as a desquamating agent, of at least one (dihydro)jasmonic acid derivative of a given formula.  Further disclosed herein is a cosmetic method for smoothing the visible and/or tactile irregularities of the skin surface, for example, for smoothing wrinkles and fine lines and/or skin spots and/or smoothing the skin, comprising topically applying, to the skin, a composition comprising, in a physiologically acceptable medium, at least one (dihydro)jasmonic acid derivative and glycerine. Other embodiments disclosed herein are novel (dihydro)jasmonic acid derivatives.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals]]></title>
<link>http://www.freepatentsonline.com/7365084.html</link>
<description><![CDATA[Provided herein are cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Biologically active peptide and agent containing the same]]></title>
<link>http://www.freepatentsonline.com/7365153.html</link>
<description><![CDATA[A peptide having any one of the amino acid sequences of SEQ ID NO: 1 or 13, preferably a peptide having any one of the amino acid sequences of SEQ ID NOS: 2 to 9 or a peptide having any one of the amino acid sequences of SEQ ID NOS: 10 and 15 to 17, is used as an active ingredient of an agent for promoting growth or differentiation of cells such as osteoblasts, chondroblasts, cementoblasts, bone marrow-derived mesenchymal stem cells and periodontal ligament-derived cells.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as β-lactamase inhibitors and antibacterials]]></title>
<link>http://www.freepatentsonline.com/7365071.html</link>
<description><![CDATA[The invention relates to novel heterocyclic compounds of general formula (I) and to their salts with a base or an acid:  
 The invention also relates to processes and to intermediates for the preparation of these compounds, and to their use as medicaments, in particular as antibacterials and β-lactamase inhibitors.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Substituted phenylindoles for the treatment of HIV]]></title>
<link>http://www.freepatentsonline.com/7365090.html</link>
<description><![CDATA[This invention is in the area of phenylindoles that are useful for the treatment of HIV infection, and, in particular, phenylindoles that exhibit significant activity against resistant strains of HIV. The phenylindoles have at least two substituents other than hydrogen on the benzo ring of the indole function, preferably at the 4′ and 5′, 5′ and 6′ or the 5′ and 7′ positions, optionally in combination with disubstitution at positions 3″ and 5″ on the phenyl ring of the compound, and carboxamide containing moieties at position-2 on the indole group of the compound. Methyl is a preferred group for substitution on the phenyl ring. Preferred substituents for the benzo ring of the indole function include but are not limited to chlorine, fluorine, bromine, iodine, CF 3 , methoxy, CN, and NO 2 .]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Indazole-derivatives as factor Xa inhibitors]]></title>
<link>http://www.freepatentsonline.com/7365088.html</link>
<description><![CDATA[The present invention relates to a compound of the formula I  
 
wherein J 1 , J 2 , R 0 , R 1 , R 2 , Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Inhibitors of p38]]></title>
<link>http://www.freepatentsonline.com/7365072.html</link>
<description><![CDATA[The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Triaza-cyclopenta[cd]indene derivatives]]></title>
<link>http://www.freepatentsonline.com/7365078.html</link>
<description><![CDATA[An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A triaza-cyclopenta[cd]indene derivative represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[N'-cyano-N-methyl-imidamide derivatives]]></title>
<link>http://www.freepatentsonline.com/7365098.html</link>
<description><![CDATA[The present invention relates to novel N′-cyano-N-methylimidamide derivatives of the general formula (I)  
 
     in which n represents 2, 3, 4 or 5, R represents optionally halogen-substituted C 1 -C 4 -alkyl, and X represents halogen, where the substituents X may in each case be identical or different,
 
to processes for their preparation and to their use as pesticides.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof]]></title>
<link>http://www.freepatentsonline.com/7365080.html</link>
<description><![CDATA[The present invention provides thieno[2,3-C]pyridine derivatives, pharmaceutical compositions comprising the thieno[2,3-C]pyridine derivatives, and methods of use thereof. The compounds capable of inhibiting glycosaminoglycan (GAG) interactions with effector cell adhesion molecules (ECAM) are useful for treating diseases and disorders mediated by GAG-ECAMs interactions, particularly inflammatory and autoimmune diseases, viral diseases, cancer, and amyloid disorders.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Endothelin antagonists]]></title>
<link>http://www.freepatentsonline.com/7365093.html</link>
<description><![CDATA[A compound of the formula (I):  
 
or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Use of pentagastrin to inhibit gastric acid secretion or as a diuretic]]></title>
<link>http://www.freepatentsonline.com/7365047.html</link>
<description><![CDATA[This invention pertains to the discovery that pentagastrin, when administered in conjunction with a proton pump inhibitor (PPI) is synergistic with the PPI and significantly increases the efficacy of the PPI in reducing/mitigating excess gastric acid secretion.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Substituted aryl acylthioureas and related compounds; inhibitors of viral replication]]></title>
<link>http://www.freepatentsonline.com/7365068.html</link>
<description><![CDATA[The invention provides compounds and pharmaceutically acceptable salts of Formula I  
 
wherein the variables A 1 , A 2 , R 1 , R 2 , V, W, X, Y, and Z are defined herein. Certain compounds of Formula I described herein which possess potent antiviral activity. The invention particularly provides compounds of Formula I that are potent and/or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents.
 The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections. The invention is particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with on or more other therapeutic agent.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Aryl sulfonamide compounds and uses related thereto]]></title>
<link>http://www.freepatentsonline.com/7365075.html</link>
<description><![CDATA[The present invention provides Aryl Sulfonamide Compounds having the formula:  
 
and prodrugs or pharmaceutically acceptable salts or prodrugs thereof. The Aryl Sulfonamide Compounds are useful for treating diabetes, obesity, and other diseases and disorders.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Modulators of melanocortin receptor]]></title>
<link>http://www.freepatentsonline.com/7365070.html</link>
<description><![CDATA[This invention provides compounds and methods for treating melanocortin receptor associated disorders, such as weight loss disorders including cachexia resulting from cancer and other chronic illnesses. The compounds are represented by formula I:  
 
wherein X is oxygen or sulfur; G is G1 or G2:
 
 
L 1 , L 2 , L 3  and Q are linker groups, and Rings A, B and C, and R 1 -R 14  are described in the specification. The compounds are antagonists of melanocortin receptors.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Compounds and methods]]></title>
<link>http://www.freepatentsonline.com/7365085.html</link>
<description><![CDATA[Disclosed is a compound having the formula:  
 
     pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[IL-1 antagonist formulations]]></title>
<link>http://www.freepatentsonline.com/7365165.html</link>
<description><![CDATA[Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion protein having an amino acid sequence selected from the group consisting of SEQ ID NO:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and 26. Most preferably, the fusion protein has the sequence of SEQ ID NO:10.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Azole derivatives]]></title>
<link>http://www.freepatentsonline.com/7365079.html</link>
<description><![CDATA[The present invention relates to a compound of the formula (I):  
 
wherein Az is a group comprising a monocyclic azole or a bicyclic aromatic ring of the same or different fused azoles; T, U, V and W are independently methine or nitrogen, said methine being optionally substituted by a substituent, and at least two of T, U, V and W are said methine groups; and X is nitrogen or methine.
 The compounds of the present invention are useful as agents for the treatment of various kinds of diseases related to NPY, for example, cardiovascular disorders, nervous system disorders, genitative diseases, metabolic diseases, genital or reproductive disorders, gastrointestinal disorders, respiratory disorders, inflammatory diseases or glaucoma, and the like.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines]]></title>
<link>http://www.freepatentsonline.com/7365082.html</link>
<description><![CDATA[It has now been found that certain novel N-(substituted aryl)-4-(disubstituted methyl)piperidine and pyridine derivatives have provided unexpected insecticidal activity. These compounds are represented by formula (I): wherein m, n, q, r, and s are independently selected from 0 or 1; and p is 0, 1, 2, or 3; A is CH or N; and B, D, E, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7  and R 8  are fully described herein. In addition, compositions comprising an insecticidally effective amount of at least one compound of formula I, and optionally, an effective amount of at least one of a second compound, with at least one insecticidally compatible carrier are also disclosed; along with methods of controlling insects comprising applying said compositions to a locus where insects are present or are expected to be present.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents]]></title>
<link>http://www.freepatentsonline.com/7365094.html</link>
<description><![CDATA[The present invention relates to compounds of the general formula (II) and salts and physiologically functional derivatives thereof,  
 
for the use as a medicament.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Liquid preparation for contact lenses]]></title>
<link>http://www.freepatentsonline.com/7364723.html</link>
<description><![CDATA[A highly safe liquid preparation for contact lenses which contains 0.3 to 50 ppm of a polyamine having recurring units of the formula (I):  
 
wherein n is 0 or 1, and which has a high antibacterial effect even at low concentrations.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX]]></title>
<link>http://www.freepatentsonline.com/7365091.html</link>
<description><![CDATA[The present invention relates to derivatives of succinic and glutaric acids and analogues thereof, having the following general formula:  
 
     useful as inhibitors of PHEX. These derivatives are useful for promoting generation of bone mass and treating or preventing diseases or conditions associated with a phosphate metabolism defect. Methods for preparation and intermediates are also disclosed.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Non-peptide GnRH antagonists]]></title>
<link>http://www.freepatentsonline.com/7365065.html</link>
<description><![CDATA[Compounds according to general formula 1, wherein A 1 -A 3  are selected from A 5  and A 6  where A 5  is either ═CR 13 — or ═N— and A 6  is —NR 14 —, —O— or —S—; A 4  is either a covalent bond or A 5 , provided that when A 4  is a covalent bond one of A 1 -A 3  must be A 6  and the other two must be A 5  and when A 4  is A 5  then all of A 1 -A 3  must be A 5 ; R 1  is selected from H, NHY′ and COY 2 , in which case R 2  is H, or R 1  and R2 may both be methyl or together represent ═O; R 3 , R 4  and R 5  are each independently selected from H and lower alkyl groups; R 6 , R 7 , R 8 , R 9 , R 10 , R 11  and R 12  are each independently selected from H, lower alkyl groups, NH 2 , halogens (F, Cl and Br) O-alkyl, CH 2 NM 2  and CF 3 ; R 13  is selected from H, F, Cl Br, NO 2 , NH 2 , OH, Me, Et, OMe, NMe 2  and CF 3 ; R 14  is selected from H, methyl and ethyl; W is selected from ═CH— and ═N—; X is selected from CH 2 , O, S, SO 2 , NH and N lower alkyl; Y 1  is selected from CO-lower alkyl, CO(CH 2 ) b Y 3 , CO(CH 2 ) b COY 3  and CO(CH)NHCOY 3 , where b is 1-3; Y2 is selected from OR 15 , NR 16 R 17  and NH(CH 2 ) C COY 3 , where c is 1-3; Y 3  is selected from OR 15  and NR 16 R 17 ; R 15  is selected from H, lower alkyl and (CH 2 ) a R 16 , where a is 0-4; R 16  and R 17  are each independently selected from H, lower alkyl and (CH 2 ) a R 16  or together are —(CH 2 ) 2 -Z-(CH 2)2 —; R 18  is OH a phenyl group or an aromatic heterocycle selected from pyridyl, pyrimidinyl, pyrazinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl and thiadiazolyl, each of which may optionally have a lower alkyl group substituent; and Z is selected from O, CH 2 , S, SO 2 , NH and N-lower alkyl, are new. They are useful in the treatment of breast and prostate cancer, endometriosis and benign prostate hyperplasia, in the regulation of fertility, and in in vitro fertilisation.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Methods for modulating a drug-related effect or behavior]]></title>
<link>http://www.freepatentsonline.com/7365050.html</link>
<description><![CDATA[The present invention provides a method of reducing or preventing a drug-related effect or behavior in a subject by inhibiting N-type calcium channels. In addition, the invention provides a variety of prescreening and screening methods aimed at identifying agents that modulate a drug-related effect or behavior. These methods involve assaying test agent binding to N-type calcium channels or channel subunits. Alternatively, test agents can be screened for their ability to alter the level of N-type calcium channels, channel subunit polypeptide or RNA, or the depolarization-induced inward calcium current mediated by these channels. Finally, the invention also provides a diagnostic method that entails measuring one or more of these levels and determining risk for a drug-related effect or behavior based on comparison to the corresponding level for a control population.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them]]></title>
<link>http://www.freepatentsonline.com/7365064.html</link>
<description><![CDATA[The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I) their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds. More particularly, the present invention relates to novel alkyl carboxylic acids of the general, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds. The present invention also relates to processes for the preparation of the compounds of formula (I), novel intermediates, processes for their preparation, their use in the preparation of the above said compounds and their use as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Pyrimidone derivatives]]></title>
<link>http://www.freepatentsonline.com/7365069.html</link>
<description><![CDATA[The present invention relates to novel pyrimidones of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. The present invention more particularly novel pyrimidones of the general formula (I)]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Triazolo-quinolin derivatives useful as adenosine receptor ligands]]></title>
<link>http://www.freepatentsonline.com/7365089.html</link>
<description><![CDATA[The present invention relates to adenosine A 3? receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and theirs salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Pyridazine, pyrimidine and pyrazine ethyne compounds]]></title>
<link>http://www.freepatentsonline.com/7365074.html</link>
<description><![CDATA[In accordance with the present invention, there is provided a novel class of heterocyclic compounds. Compounds of the invention contain a substituted, unsaturated five, six or seven membered heterocyclic ring that includes at least one nitrogen atom and at least one carbon atom. The ring additionally includes three, four or five atoms independently selected from carbon, nitrogen, sulfur and oxygen atoms. The heterocyclic ring has at least one substituent located at a ring position adjacent to a ring nitrogen atom. This mandatory substituent of the ring includes a moiety (B), linked to the heterocyclic ring via a carbon-carbon double bond, a carbon-carbon triple bond or an azo group. The mandatory substituent is positioned adjacent to the ring nitrogen atom. Invention compounds are capable of a wide variety of uses. For example heterocyclic compounds can act to modulate physiological processes by functioning as agonists and antagonists of receptors in the nervous system. Invention compounds may also act as insecticides, and as fungicides. Pharmaceutical compositions containing invention compounds also have wide utility.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Chromane and chromene derivatives and uses thereof]]></title>
<link>http://www.freepatentsonline.com/7365095.html</link>
<description><![CDATA[Compounds of formula I or pharmaceutically acceptable salts thereof are provided:  
 
wherein each of R 1 , R 2 , R 3 , R 4 , y, m, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Quinazolinone and benzoxazinone derivatives and uses thereof]]></title>
<link>http://www.freepatentsonline.com/7365063.html</link>
<description><![CDATA[Compounds of the formula I:  
 
and pharmaceutically acceptable salts thereof wherein X is N, Y is S, Z is —(CR a R b ) r —, A is —NR 3 , m is 2, n is 1, q is 2, R 2  is optioinally substituted aryl or optionally substituted heteroaryl, and p, R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 , are as defined herein. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula I for treatment of central nervous system diseases.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Ceramic based nanoparticles for entrapping therapeutic agents for photodynamic therapy and method of using same]]></title>
<link>http://www.freepatentsonline.com/7364754.html</link>
<description><![CDATA[The present invention provides methods and compositions for photodynamic therapy. The composition comprises ceramic nanoparticles in which a photosensitive drug/dye is entrapped. The ceramic nanoparticles are made by formation of a micellar composition of the dye. The ceramic material is added to the micellar composition and the ceramic nanoparticles are precipitated by alkaline hydrolysis. The precipitated nanoparticles in which the photosensitive dye/drug is entrapped can be isolated by dialysis. The resulting drug doped nanoparticles are spherical, highly monodispersed, and stable in aqueous system. Irradiation with light of suitable wavelength of the photosensitizing drug entrapped inside nanoparticles resulted in generation of singlet oxygen, which was able to diffuse out through the pores of the ceramic matrix. The drug loaded ceramic nanoparticles of the present invention can be used as drug carriers for photodynamic therapy.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Use of PAK inhibitor for the treatment of a joint disease]]></title>
<link>http://www.freepatentsonline.com/7364887.html</link>
<description><![CDATA[The invention refers to the use of a p21-activated kinase (PAK) inhibitor for the treatment of a joint disease such as osteoarthritis or rheumatoid arthritis or for the treatment of a joint pain and the use of PAK as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor]]></title>
<link>http://www.freepatentsonline.com/7365077.html</link>
<description><![CDATA[Disclosed are piperazine bis-amide derivatives useful as antagonists of the orexin receptor and pharmaceutical compositions containing the same.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4]]></title>
<link>http://www.freepatentsonline.com/7365073.html</link>
<description><![CDATA[Disclosed are certain 3-(heteroaryl)alanine derivatives which bind VLA-4 and inhibit leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Adiponectin and uses thereof]]></title>
<link>http://www.freepatentsonline.com/7365170.html</link>
<description><![CDATA[The invention provides methods and reagents for regulation of metabolic events, such as those mediated by adiponectin and adiponectin agonists. The invention also provides screening assays for identification of biologically active agents, diagnostic and therapeutic agents, and other methods and reagents.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Amide derivatives as NMDA receptor antagonists]]></title>
<link>http://www.freepatentsonline.com/7365083.html</link>
<description><![CDATA[Compounds having NR2B selective NMDA receptor antagonist activity are disclosed of the formula (I)  
 
wherein
 
     two of the neighboring R 1 , R 2 , R 3  and R 4  groups form an oxo-oxazolidine ring fused to the benzene ring of the indole nucleus, and the other two of R 1 , R 2 , R 3  and R 4  groups are hydrogen atoms, R 5  and R 6  together with the nitrogen between them form a saturated or unsaturated, 4-6 membered heterocyclic ring, which is substituted by phenoxy, phenyl-(C 1 -C 4  alkyl), phenyl-(C 1 -C 4  alkoxy), phenoxy-(C 1 -C 4  alkyl), or benzoyl, optionally substituted on the aromatic ring by one or more halogen atoms, cyano or hydroxy groups, C 1 -C 4  alkyl or C 1 -C 4  alkoxy groups, X is NH—, Y is a —CH— group, or pharmaceutically acceptable salts thereof formed with acids or bases.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Substituted aryl cycloalkanol derivatives and methods of their use]]></title>
<link>http://www.freepatentsonline.com/7365076.html</link>
<description><![CDATA[The present invention is directed to substituted aryl cycloalkanoyl derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Indanol derivative]]></title>
<link>http://www.freepatentsonline.com/7365067.html</link>
<description><![CDATA[The present invention provides a compound having the following general formula (I) which is useful as a neurokinin receptor antagonist:  
 
(wherein,
 
     R 1 , R 2 : optionally substituted (hetero)aryl, R 3 : —CO—R 4 , —CO—O—R 4 , etc., R 4 : alkyl, cycloalkyl, etc., A: CH 2 , CO, SO 2 , B: a single bond, etc., D: oxygen, CH 2 , E: alkylene, alkenylene, n: 1 to 3).]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Oxazole derivatives of tetracyclines]]></title>
<link>http://www.freepatentsonline.com/7365087.html</link>
<description><![CDATA[This invention provides compounds of the formula:  
 
wherein A″, X and Y are defined in the specification. These compounds are useful as antibacterial agents.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Nonpeptide substituted spirobenzoazepines as vasopressin antagonists]]></title>
<link>http://www.freepatentsonline.com/7365062.html</link>
<description><![CDATA[The invention is directed to nonpeptide substituted benzodiazepines of Formula I,  
 
wherein A, X, n, R 1 , R 2 , R 3 , R 4 , R 5 , a and b are as described in the specification, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, cerebral edema and ischemia, stroke, thrombosis, or water retention are also disclosed.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Compounds with improved cartilage-inducing and/or bone-inducing activity]]></title>
<link>http://www.freepatentsonline.com/7365051.html</link>
<description><![CDATA[The present invention concerns a bioactive implant material having a cartilage-inducing and/or bone-inducing activity composed of two components A and B, of which A is a bone-inducing and/or cartilage-inducing protein or protein mixture and preferably one or several proteins from the TGF-β superfamily, preferably MP52 or a DNA sequence coding therefor and B is a carrier matrix composed of calcium phosphate ceramics with an interconnecting microporosity which already alone has bone-inducing properties. The invention additionally concerns the production of these compounds and their use for the treatment of diseases which affect cartilage and/or bones as well as to treat damage to cartilage and/or bone tissue.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies]]></title>
<link>http://www.freepatentsonline.com/7365054.html</link>
<description><![CDATA[The invention provides methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Inhibitors of serine proteases, particularly HCV NS3-NS4A protease]]></title>
<link>http://www.freepatentsonline.com/7365092.html</link>
<description><![CDATA[The present invention relates to compounds of formula I:  
 
or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Compositions for the treatment of acquired immunodeficiency disease]]></title>
<link>http://www.freepatentsonline.com/7364760.html</link>
<description><![CDATA[This invention relates to compositions for the treatment of acquired immunodeficiency diseases, especially human immunodeficiency virus (HIV), and its simian and feline counterparts (simian immunodeficiency virus (SIV), and feline immunodeficiency virus (FIV)), and to methods for their use.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Pyridine-3-sulfonyl compounds as pesticidal agents]]></title>
<link>http://www.freepatentsonline.com/7365042.html</link>
<description><![CDATA[The present invention describes novel pyridine-3-sulfonyl compounds having the formula (I)  
 
wherein R 1 , R 2 , R 3 , R 4  and R 5  are as defined herein.
 The present invention is also directed lo pesticidal compositions that include a) compounds of formula (II) 
 
wherein R 1 , R 2 , R 3 , R 4  and R 6  are as defined herein and b) a carrier.
 Moreover, the present invention relates to methods for protecting crops from insect attack by contacting the crop with a pesticidally effective amount of the compound of formula (II). In addition, the present invention includes methods for controlling insects by treating the target species with a pesticidally effective amount of the compound of formula (II).]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Substituted 9a-N-(N′-(sulfonyl)phenylcarbamoyl)derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithomycin A and 5-0-desosaminyl-9-deoxo-9-dihydro-9-a-aza-9a-homoerithronolide A]]></title>
<link>http://www.freepatentsonline.com/7365056.html</link>
<description><![CDATA[The invention relates to substituted 9a-N-{N′-[4-(sulfonyl)phenyl]carbamoyl} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-0-desosaminyl-9-deoxo-9-di-hydro-9a-aza-9a-homoerithronolide A, novel semisynthetic macrolide antibiotics of the azalide series general formula (1), wherein R represents H or cladinosyl moiety and R1 represents chloro, amino, phenylamino, 2-pyridylamino, 3,4-dimethyl-4-isoxalylamino and 5-methyl-3-isoxazolylamino group, and pharmaceutically acceptable addition salts thereof with inorganic or organic acids. to the process for their preparation of pharmaceutical composition as well as the use their compositions for sterilization rooms and medical instruments as well as for protection of wall and wooden coatings]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Endothelial cells engineered to express or overexpress fibulin-5 and a growth factor]]></title>
<link>http://www.freepatentsonline.com/7364725.html</link>
<description><![CDATA[The present invention relates to endothelial and smooth muscle cells genetically altered to express or over-express one or more cell adhesion factors. The invention further relates to cells genetically altered to express or over-express both cell proliferation growth factor(s) and cell adhesion factor(s). In addition, the present invention relates to nucleic acid constructs and nucleic acid construct systems that encode the cell adhesion and cell proliferation growth factors and that are used to transfect/transform the cells so that they can express the factors.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[MicroRNA and methods for inhibiting same]]></title>
<link>http://www.freepatentsonline.com/7365058.html</link>
<description><![CDATA[The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Derivatives of morphine-6-glucuronide, pharmaceutical compositions containing them, their preparation method and their uses]]></title>
<link>http://www.freepatentsonline.com/7365055.html</link>
<description><![CDATA[The invention relates to novel derivatives of morphine-6-glucuronide, the preparation method thereof and the uses of same in therapy, for example, as analgesics.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Methods of inducing ovulation]]></title>
<link>http://www.freepatentsonline.com/7364910.html</link>
<description><![CDATA[The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Pharmaceutical and cosmetic compositions comprising plgf-1]]></title>
<link>http://www.freepatentsonline.com/7364722.html</link>
<description><![CDATA[The invention relates to the preparation of placental growth factor (PLGF)-comprising therapeutic and cosmetic compositions capable of increasing angiogenesis of the cutaneous, subcutaneous and internal organ connective tissue. Such compositions are suitable for the treatment of pathological or natural states benefiting from the formation or regeneration of new vessels of the cutaneous compartment, such as scleroderma, its various manifestations, skin aging or loss of hair.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Wit 3.0, a novel gene to control soft tissue wound healing]]></title>
<link>http://www.freepatentsonline.com/7365175.html</link>
<description><![CDATA[The present invention provides a method of treatment to improve wound healing and to minimize/prevent abnormal scarring caused by tissue contraction and fibrosis formation by providing a specific gene, Wit 3.0 alpha and beta sequences that is differentially expressed in wounded oral mucosa cells, relative to their decreased expression in non-wounded oral mucosa cells. One aspect of the invention is a method to treat soft tissue wound using anti-sense nucleic acid technologies. Another aspect of the present invention is a method to treat soft tissue wound using sense nucleic acid technologies. These methods can employ a complimentary nucleic acid sequence that is greater than 85% identity to Wit 3.0 alpha and/or beta sequences or greater than 90% identity to the deduced amino acids thereof.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Loop peptide and TGFα for stimulating stem cell proliferation and migration]]></title>
<link>http://www.freepatentsonline.com/7365172.html</link>
<description><![CDATA[There is disclosed a novel genus of small peptides, much smaller than human TGFα, was discovered as having TGFα biological activity and therefore are useful as pharmacologic agents for the same indications as full length TGFα polypeptide. There is further disclosed that TGFα and consequently the genus of small peptides disclosed herein, was found to have therapeutic activity to stimulate hematopoiesis in patients undergoing cytotoxic cancer chemotherapy and to act as a cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal (GI) side effects, such as mucositis and otherwise support the barrier function of the GI tract when it is harmed by cytotoxic therapy.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Stabilized bioactive peptides and methods of identification, synthesis, and use]]></title>
<link>http://www.freepatentsonline.com/7365162.html</link>
<description><![CDATA[An intracellular selection system allows screening for peptide bioactivity and stability. Randomized recombinant peptides are screened for bioactivity in a tightly regulated expression system, preferably derived from the wild-type lac operon. Bioactive peptides thus identified are inherently protease- and peptidase-resistant. Also provided are bioactive peptides stabilized by a stabilizing group at the N-terminus, the C-terminus, or both. The stabilizing group can be a small stable protein, such as the Rop protein, glutathione sulfotransferase, thioredoxin, maltose binding protein, or glutathione reductase, an α-helical moiety, or one or more proline residues.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Method for treating inflammation]]></title>
<link>http://www.freepatentsonline.com/7364732.html</link>
<description><![CDATA[A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its receptor or a soluble receptor that binds to IL-20. Examples of such diseases are adult respiratory disease, psoriasis, eczema, contact dermatitis, atopic dermatitis, septic shock, multiple organ failure, inflammatory lung injury, bacterial pneumonia, inflammatory bowel disease, rheumatoid arthritis, asthma, ulcerative colitis and Crohn's disease.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Peptides of human Papilloma virus for use in human T cell response inducing compositions]]></title>
<link>http://www.freepatentsonline.com/7364741.html</link>
<description><![CDATA[A peptide comprising an amino acid sequence derived from a human papilloma virus (HPV) protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex Class I molecule. Its use in prophylactic or therapeutic treatment of cervical carcinoma and other HPV-related diseases.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

<item>
<title><![CDATA[Molecular differences between species of the <i>M. tuberculosis </i>complex]]></title>
<link>http://www.freepatentsonline.com/7364740.html</link>
<description><![CDATA[Specific genetic deletion are identified in mycobacteria isolates, including variations in the  M. tuberculosis  genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from  M. bovis  or  M. tuberculosis  to attenuate the pathogenic bacteria.]]></description>
<pubDate>April 29, 2008</pubDate>
</item>

</channel>
</rss>
